Objective To investigate expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and endoglin (CD105) in renal cell carcinoma (RCC), and their potential role in predicting the tumor growth and progression. Method Total of 47 RCC specimens and 15 adjacent normal kidney tissues were obtained. Expression of CEACAM1 and CD105 was assessed by immunohistochemistry. Microvessel density (MVD) was counted under the microscope by labeling the endothelial cells with biomarker, CD34. Result Positivity of CEACAM1 expression in RCC (42.6%) was significantly lower than that in the normal kidney (73.3%, P = 0.038). In contrast, positivity of CD105 expression was significantly higher in RCC (78.7%) compared to that in normal kidney tissue (46.7%, P = 0.017). Expression level of CD105 in 47 RCC was significantly associated with clinical stages of RCC (P < 0.05), but not with gender, age, the tumor size and histologic grade. Average MVD in RCC (78.05 ± 16.57) was significantly higher than that in normal tissues (43.62 ± 12.37, P < 0.05), and was significantly higher in the RCC with advanced histologic grades (P < 0.05) or clinical stages (P < 0.01). In addition, MVD was significantly correlated with CD105, but negatively correlated with CEACAM1. Conclusion Findings of the current study suggested that down regulation of CEACAM1 may contribute to the promotion of angiogenesis in RCC, and that up regulation of CD105 may promote RCC progress. MVD could be an indicator of the malignancy of RCC.

中文翻译：

---

CEACAM1、CD105在肾细胞癌中的表达及其与微血管密度的相关性

目的探讨癌胚抗原相关细胞粘附分子1（CEACAM1）和内皮糖蛋白（CD105）在肾细胞癌（RCC）中的表达及其在预测肿瘤生长进展中的潜在作用。方法共获得47个RCC标本和15个相邻的正常肾组织。通过免疫组织化学评估 CEACAM1 和 CD105 的表达。通过用生物标志物 CD34 标记内皮细胞，在显微镜下计算微血管密度 (MVD)。结果 RCC中CEACAM1表达阳性率（42.6%）显着低于正常肾脏（73.3%，P=0.038）。相比之下，与正常肾组织（46.7%，P = 0.017）相比，RCC 中 CD105 表达的阳性率（78.7%）显着更高。CD105 在 47 例 RCC 中的表达水平与 RCC 的临床分期显着相关（P < 0.05），但与性别、年龄、肿瘤大小和组织学分级无关。RCC的平均MVD（78.05±16.57）显着高于正常组织（43.62±12.37，P < 0.05），并且在具有晚期组织学分级（P < 0.05）或临床分期（P < 0.01）的RCC中显着更高）。此外，MVD与CD105显着相关，而与CEACAM1呈负相关。结论 本研究结果提示CEACAM1下调可能促进RCC血管生成，CD105上调可能促进RCC进展。MVD 可能是 RCC 恶性程度的一个指标。RCC的平均MVD（78.05±16.57）显着高于正常组织（43.62±12.37，P < 0.05），并且在具有晚期组织学分级（P < 0.05）或临床分期（P < 0.01）的RCC中显着更高）。此外，MVD与CD105显着相关，而与CEACAM1呈负相关。结论 本研究结果提示CEACAM1下调可能促进RCC血管生成，CD105上调可能促进RCC进展。MVD 可能是 RCC 恶性程度的一个指标。RCC的平均MVD（78.05±16.57）显着高于正常组织（43.62±12.37，P < 0.05），并且在具有晚期组织学分级（P < 0.05）或临床分期（P < 0.01）的RCC中显着更高）。此外，MVD与CD105显着相关，而与CEACAM1呈负相关。结论 本研究结果提示CEACAM1下调可能促进RCC血管生成，CD105上调可能促进RCC进展。MVD 可能是 RCC 恶性程度的一个指标。MVD 与 CD105 显着相关，但与 CEACAM1 呈负相关。结论 本研究结果提示CEACAM1下调可能促进RCC血管生成，CD105上调可能促进RCC进展。MVD 可能是 RCC 恶性程度的一个指标。MVD 与 CD105 显着相关，但与 CEACAM1 呈负相关。结论 本研究结果提示CEACAM1下调可能促进RCC血管生成，CD105上调可能促进RCC进展。MVD 可能是 RCC 恶性程度的一个指标。